Resources Case Studies Coding & Billing Implementation Tools Package Inserts Product Information Videos, Webinars, & Podcasts Select ProductPlateletsAll ProductsIFCPlasmaPlateletsPRPCRSelect Resource TypeAll Resource TypesCase StudiesCoding & BillingImplementation ToolsPackage InsertsProduct InformationVideos, Webinars, & PodcastsUINTERCEPT Goes Beyond – Platelets and IFCTransfusion ServicesElevate Patient Care for Hematology-Oncology PatientsINTERCEPT Blood System Mechanism of ActionAssessing Platelet Availability – PR vs. LVDSUse of PR Platelets for Patient Safety and SustainabilityUS Tertiary Care Hospital Gains Operational Efficiency and Fresher PlateletsOptimizing Platelet Availability and Access to 100% PR InventoryVersiti PR Scale-UpImplementation of PR at Puerto Rico Blood Center During Zika OutbreakStanford Blood Center Implements 100% PRPlatelets and Plasma Outpatient Information GuideISBT Platelets CodesBest Practices Platelet Handling Guide – HospitalsPR Platelets Implementation GuideSample Labels SheetSample SBAR SheetSample Tie Tags SheetNurse Training ModuleImplementing INTERCEPT Platelets – E-learning TestNurse Handout TemplatePlatelets Small Volume (SV) – INT2130BPlatelets Large Volume (LV) – INT2230BPlatelets Dual Storage (DS) – INT2530BPlatelets Dual Storage (DS) Semi-Integrated Set – INT2540BPlatelets Small Volume (SV) Semi-Integrated Set – INT2140BPlatelets Large Volume (LV) Semi-Integrated Set – INT2240BINTERCEPT Integrated Sets Specifications InsertInterview: Dr. Maria De Los Angeles MuñizINTERCEPT Plasma Specifications InsertINTERCEPT Blood System for PlateletsInterview: Dr. Shannon WalkerInterview: Dr. Deva SharmaINTERCEPT Platelets Safety and EfficacyINTERCEPT Semi-integrated Sets Specifications InsertPR – Proactive Strategy for Blood Safety in Pandemic PreparationMethodologies for Reducing the Risk of TA-GVHD from Platelet TransfusionsCMV Mitigation SheetINTERCEPT Platelets InfographicWhy Blood Safety Matters: An Interview with Dr. Jerry SquiresRise in incidence of emerging arthropod-borne viruses: Eastern equine encephalitis and OropoucheLogistical Management of Incorporating Pathogen Reduced Platelets into Inventory – Yale New-Haven HospitalSafety and Efficacy of Amotosalen-UVA PR Platelet Components Transfused to Mature and Premature Neonates – Cerus CorporationPhased Implementation of Pathogen-Reduced Platelets – UCSDThe Effects of PAS and PR on Platelet Use – Roswell Park Cancer InstituteComparing Useable Shelf-life of PR Platelets vs LVDS Screened PlateletsImpact of PR vs LVDS Testing on Platelet AvailabilityPlatelets Economic Model – RutgersImpact of Amotosalen/UVA Process for PR in PLT Concentrates on Transfusion Efficiency in Cardiac Surgery – Saint-Etienne, France2025 ISBT Abstract Book2024 AABB Abstract BookINTERCEPT Platelets Publications2022 AABB Abstract BookSeptic Transfusion Reaction Awareness2023 AABB Abstract BookThe PIPER Phase IV Study: Assessing the Safety of Pathogen Reduced Platelets in a Large Study of Platelet Transfusion-Associated Pulmonary InjuryLocal transmission of dengue virus – considerations for blood safety and the role of PRFibrinogen Supplementation in Hemorrhagic Shock: Role of INTERCEPT® Fibrinogen ComplexPathogen Reduced Cryoprecipitated Fibrinogen Complex (INTERCEPT® Fibrinogen Complex or IFC) and INTERCEPT® treated Platelets: Expanding the Use of Pathogen Reduction for Improved Blood SafetyPreparing Our Blood Supply for the Next Pandemic with Dr. Susan StramerImplementing Pathogen Reduced Platelets: A TSO (Transfusion Safety Officer) Perspective (Johns Hopkins All Children’s Hospital)Implementing Pathogen Reduced Platelets: A TSO (Transfusion Safety Officer) Perspective (Allegheny Health Network)Pathogen Reduction of Platelets: Patient Safety and FDA Platelet Bacterial Guidance CompliancePathogen Reduction of Platelets: Guidance Compliance and ImplementationEvaluating Usable Shelf-Life of Pathogen Reduced and LVDS Tested Platelet ComponentsImplementing Pathogen Reduced (PR) INTERCEPT Platelets and Pediatric ConsiderationsPathogen Reduced Platelet Implementation at Stanford HospitalPlatelet Component Bacterial Risk Control: An Evolution in ProgressPlatelet Pathogen Reduction Technology Implementation at Stanford Blood CenterImpact of Anaerobic Culture of Platelets on Safety and OperationsMerits and Pitfalls of Automated Bacterial Culture Methods in Improving Bacterial Safety of Platelet ConcentratesImpact of Platelet Transfusion on Pulmonary Function of Hematology Oncology Patients: The PIPER StudyHemostatic Efficacy of Pathogen Reduced Platelets in Pediatric Cardiopulmonary BypassReview of Neonate to Pediatric Patient Outcomes Transfused with Amotosalen/UVA Treated PlateletsAssessing Platelet Availability from Blood Center and Hospital PerspectivesUpdating a Software Model to Estimate the Cost and Shelf Life Implications of New Platelet TechnologiesThe Rationale for Pathogen Reduction: Blood Center and Transfusion Services PerspectivesThe INTERCEPT Blood System Mechanism of Action
Logistical Management of Incorporating Pathogen Reduced Platelets into Inventory – Yale New-Haven Hospital
Safety and Efficacy of Amotosalen-UVA PR Platelet Components Transfused to Mature and Premature Neonates – Cerus Corporation
Impact of Amotosalen/UVA Process for PR in PLT Concentrates on Transfusion Efficiency in Cardiac Surgery – Saint-Etienne, France
The PIPER Phase IV Study: Assessing the Safety of Pathogen Reduced Platelets in a Large Study of Platelet Transfusion-Associated Pulmonary Injury
Pathogen Reduced Cryoprecipitated Fibrinogen Complex (INTERCEPT® Fibrinogen Complex or IFC) and INTERCEPT® treated Platelets: Expanding the Use of Pathogen Reduction for Improved Blood Safety
Implementing Pathogen Reduced Platelets: A TSO (Transfusion Safety Officer) Perspective (Johns Hopkins All Children’s Hospital)
Implementing Pathogen Reduced Platelets: A TSO (Transfusion Safety Officer) Perspective (Allegheny Health Network)
Merits and Pitfalls of Automated Bacterial Culture Methods in Improving Bacterial Safety of Platelet Concentrates
Impact of Platelet Transfusion on Pulmonary Function of Hematology Oncology Patients: The PIPER Study
Updating a Software Model to Estimate the Cost and Shelf Life Implications of New Platelet Technologies